Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Insiders own 30 percent of all shares.
It states on the error message that the account is suspended....
I'm thinking an update is in the works.
Feel free to update your comment on selloff....
Yes you do......
I'd say you are wrong.
Don't worry coach, we will find a pretty girl to take care of you.
I had my eye on a blue one, also placing an order for a garbage bag full and the ladies to carry it in.
Does anyone know what SBFMD is all about.
Is this something we should be buying?
Make sure you have access to the appropriate safety gear......
PATENT & FDA APPROVED UPLISTING and OS reduced 78M! COVID19
PATENT APPROVAL & FDA SUBMISSION APPROVAL FOR SBFM!!!! HUGE
10-Q last week reduced O/S by 28%!!!!!!!!!!!!
UPLISTING TO NYSE
Sunshine Biopharma is a huge covid-19 play!!!!
Found this on Stockhouse
Lets be positive today and assume that we will have news and approvals and this thing is going to launch this afternoon.
I will await its next post for the next lot of shares to add to my stack
Same.
When I see fish I buy shares, like clockwork
I'm loaded and long.
Have been since I arrived and will continue to do so.
Whats that, whales are peeing in the pool.
YUCK
better stay in the deep end for a bit until the water returns to normal.....
Just repeating the words of others
No...........
Not till October..
LOL
Well looks like some folks will take the word of others for no given reason. Makes me sick to know they keep bailing out the cause of this turmoil, giving the opportunity for wash rinse and repeat.
Chair set,deposit slip at the ready.
Today is the day we settle in and start to understand the direction of this company and the financial impacts of the current status of the organization. I do hope it provide a snapshot into the future in terms of patents and expectations with sales of the generic drugs. As far as up listing goes, this will take care of itself but will not limit the profits that can be make in the short term.
We know there is huge potential here, today is the day we better understand how things will unfold.
There are several things that can be confirmed in the filings that are due today, I think there will be some form of confirmation on the patent and possibly some info on a possible buy out or joint venture.
I have been patient but now I'm getting excited at understanding the possibilities of what we own.
JMO
https://www.otcshortreport.com/company
See here for short numbers
This stock gets shorted on average 50 to 60 percent of daily volume
I've been in for a long time with a healthy position.
Hope all have a good weekend; looking forward to next weeks excitement.
shhhhhhhhhh
traders trading, a hush falls over the crowd.
Up ?
Down?
Feels like a bounce, hopefully headed above yesterdays close.
Feels like a bounce, hopefully headed above yesterdays close.
Thank you for that and I agree on the motive.
What do you mean by POS?
Today this is like a heavy beer drinkers zipper.
Thank god you provided the correction to the worldly balance.
Its not a company rather a drug that SBFM created
MINNEAPOLIS, June 30, 2020 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic cancer, today announced receipt of Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its lead product, SBP-101, being developed for first-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDA) when administered in combination with gemcitabine and nab-paclitaxel.
One of FDA’s Expedited Programs for Serious Conditions, Fast Track is a process designed to facilitate the development and potentially expedite the review of drugs intended to treat serious conditions and address unmet medical needs. Programs with Fast Track Designation may benefit from more frequent meetings with and written communications from FDA, in addition to being eligible for accelerated approval and priority review if certain criteria are met. Fast Track Designation also provides eligibility for a rolling review of a New Drug Application (NDA), which allows for completed sections of an NDA to be submitted for FDA review. Usually NDA review does not begin until the company has submitted the entire application to the FDA.
“Fast Track Designation is important for Sun BioPharma because it enhances our ability to develop SBP-101 as efficiently as possible,” said Suzanne Gagnon, M.D., Chief Medical Officer of Sun BioPharma. Michael T. Cullen, M.D., MBA, Co-Founder, Executive Chairman, and CEO, added “There is an urgent need for new therapeutic options for patients with pancreatic cancer, and we look forward to working closely with FDA as we continue to advance our development program of SBP-101 for patients with metastatic PDA.”
SBP-101 is currently being evaluated in a Phase 1a/1b clinical trial of patients with previously untreated metastatic PDA at sites in the United States and Australia. For more information please visit clinicaltrials.gov.
About SBP-101
SBP-101 is a proprietary polyamine analogue designed to be a first-in-class product to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for the exocrine pancreas and pancreatic ductal adenocarcinoma. The molecule has shown signals of tumor growth inhibition in clinical studies of US and Australian metastatic pancreatic cancer patients, suggesting complementary activity with an existing FDA-approved chemotherapy regimen. In clinical studies to date, SBP-101 has not shown exacerbation of the typical chemotherapy-related adverse events of bone marrow suppression and peripheral neuropathy. The safety data and PMI profile observed in Sun BioPharma’s current clinical trial provides support for continued evaluation of the compound in a randomized clinical trial.
Turn off your portable devices,keep taking to a minimum.
Others are getting ready for the show.....SHHHHHHHHHH
We are close to the top of most posted and most read,the people and money are on their way.
As per our discussions this week, no drinking and driving as you celebrate the goods things pending here, Johnny law is not as forgiving as he used to be. It would be a shame to have to use your profits to pay legal fees and chauffeurs for the next few years.
We all have this demon that forces us to hold out for bigger and better things. We all forget we started out with nothing.
A dollar in the hand is better than missing out on millions.
Human nature is hard to sway.
Well put.
I wanted to add to your sentiments,make sure you consider taking profits as the ride continues, I'm sure there will be ample dips throughout the wild ride.
Yuck................
Climbing the most posted and most read, eyes are here.
Go away